AMGN

Amgen Inc.

Halal Rating :
Uncomfortable
See Details
Last Price $283.60 Last updated:
Market Cap $172.1b
7D Change -12.81%
1 Year Change 5.43%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange Nasdaq
Next Earnings Date Nov. 5, 2024

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $8.5b $7.23b - $776.0m 0.00% 10.73%
June 30, 2024 $8.39b $7.29b - $808.0m 0.00% 11.09%
March 31, 2024 $7.45b $7.28b - $824.0m 0.00% 11.32%

Company Impact

Help us evaluate Amgen Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Justification for our Halal Rating

Contribute

Recent News & Updates